3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
114
Lung Neoplasms
83
Lymphoma
76
Head and Neck Neoplasms
76
Glioblastoma
75
Squamous Cell Carcinoma of Head and Neck
71
Breast Neoplasms
71
Rectal Neoplasms
67
Esophageal Neoplasms
63
Prostatic Neoplasms
59
Leukemia
57
Central Nervous System Neoplasms
54
Pancreatic Neoplasms
51
Precursor Cell Lymphoblastic Leukemia-Lymphoma
47
Lymphoma, Non-Hodgkin
43
Lymphoma, Large B-Cell, Diffuse
43
Hodgkin Disease
42
Lymphoma, Follicular
41
Brain Neoplasms
40
Leukemia, Lymphocytic, Chronic, B-Cell
39
Esophageal Squamous Cell Carcinoma
39
Colorectal Neoplasms
38
Burkitt Lymphoma
37
Gliosarcoma
36
Lymphoma, Large-Cell, Immunoblastic
33
Uterine Cervical Neoplasms
31
Neoplasms
31
Adenocarcinoma Of Esophagus
31
Lymphoma, Mantle-Cell
30
Lymphoma, B-Cell, Marginal Zone
29
Interventions
Trastuzumab
5
Carboplatin
5
130-nm albumin-bound paclitaxel
3
toripalimab
2
pertuzumab
2
pembrolizumab
2
Tretinoin
2
Paclitaxel
2
Immunotherapy
2
Drug Therapy
2
Doxorubicin
2
Docetaxel
2
Cytarabine
2
zanidatamab
1
venetoclax
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
tislelizumab
1
temsirolimus
1
talazoparib
1
tagraxofusp
1
sarilumab
1
sargramostim
1
pyrotinib
1
pexidartinib
1
pazopanib
1
patritumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Pathologic Complete Response
×
Radiotherapy
×
Clear all
NCT02353858
2018-02-13
HT01
University Hospital Tuebingen
Phase 2
Completed
78 enrolled